Articles dans des revues avec comité de lecture (127)
  1. 58. Duret, C., Wauthoz, N., Sebti, T., Vanderbist, F., & Amighi, K. (2012). New Inhalation-Optimized Itraconazole Nanoparticle-Based Dry Powders for the Treatment of Invasive Pulmonary Aspergillosis. International journal of nanomedicine, 7, 5475–5489. doi:10.2147/IJN.S34091
  2. 59. Reeff, J., Gaignaux, A., Goole, J., De Vriese, C., & Amighi, K. (2012). New sustained-release intraarticular gel formulations based on monolein for local treatment of arthritic diseases. Drug development and industrial pharmacy. doi:10.3109/03639045.2012.730529
  3. 60. Duret, C., Wauthoz, N., Merlos, R., Goole, J., Maris, C., Roland, I., Sebti, T., Vanderbist, F., & Amighi, K. (2012). In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice. European journal of pharmaceutics and biopharmaceutics, 81(3), 627-634. doi:10.1016/j.ejpb.2012.04.004
  4. 61. Gaignaux, A., Reeff, J., Siepmann, F., Siepmann, J., De Vriese, C., Goole, J., & Amighi, K. (2012). Development and evaluation of sustained-release clonidine-loaded PLGA microparticles. International journal of pharmaceutics, 437(1-2), 20-28. doi:10.1016/j.ijpharm.2012.08.006
  5. 62. Lamoral-Theys, D., Wauthoz, N., Heffeter, P., Mathieu, V., Jungwirth, U., Lefranc, F., Neve, J., Dubois, J., Dufrasne, F., Amighi, K., Berger, W., Gailly, P., & Kiss, R. (2012). Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca 2+ release. Journal of Cellular and Molecular Medicine, 16(7), 1421-1434. doi:10.1111/j.1582-4934.2011.01403.x.
  6. 63. Duret, C., Wauthoz, N., Sebti, T., Vanderbist, F., & Amighi, K. (2012). New Respirable and Fast Dissolving Itraconazole Dry Powder Composition for the Treatment of Invasive Pulmonary Aspergillosis. Pharmaceutical research, 29(10), 2845-2859. doi:10.1007/s11095-012-0779-4
  7. 64. Duret, C., Wauthoz, N., Sebti, T., Vanderbist, F., & Amighi, K. (2012). Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. International journal of pharmaceutics, 428(1-2), 103-113. doi:10.1016/j.ijpharm.2012.03.002
  8. 65. Pilcer, G., Wauthoz, N., & Amighi, K. (2012). Lactose characteristics and the generation of the aerosol. Advanced drug delivery reviews, 64(3), doi:10.1016/j.addr.2011.05.003, 233–256.
  9. 66. Depreter, F., Burniat, A., Blocklet, D., Lacroix, S., Cnop, M., Fery, F., Van Aelst, N., Pilcer, G., Deleers, M., Goldman, S., & Amighi, K. (2012). Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. European journal of pharmaceutics and biopharmaceutics, 80(1), 4-13. doi:10.1016/j.ejpb.2011.09.015
  10. 67. Wauthoz, N., Deleuze, P., Saumet, A., Duret, C., Kiss, R., & Amighi, K. (2010). Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment. Pharmaceutical research, 28(4), 762-75. doi:10.1007/s11095-010-0329-x
  11. 68. Depreter, F., & Amighi, K. (2010). Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration. European journal of pharmaceutics and biopharmaceutics, 76(3), 454-463. doi:10.1016/j.ejpb.2010.08.005
  12. 69. Pilcer, G., & Amighi, K. (2010). Formulation strategy and use of excipients in pulmonary drug delivery. International journal of pharmaceutics, 392(1-2), 1-19. doi:10.1016/j.ijpharm.2010.03.017
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Suivant >>